

CF-AIR & CF@LANTA NEWSLETTER

Cystic Fibrosis Center of Excellence

Emory University - Children's Healthcare of Atlanta -
Georgia Tech - Augusta Univ. - Georgia State - UGA




SEPTEMBER 2026



Director's Update

Dr. Nael McCarty



Dear friends and colleagues,

We hope this newsletter finds you well.

This past week was a huge week for CF@LANTA, as several members from four institutions teamed up to submit the largest NIH research proposal in our team's history. This was for an NIH "Program Project Grant," with a budget of \$10.25M over five years. The focus is on non-CF bronchiectasis (NCFBE), an area of very strong interest for the NIH as this disease is very poorly described at the mechanistic level, compared to CF, and impacts roughly 30X as many people as CF. Why would a CF-focused team do this? Well, bronchiectasis is what causes most of the morbidity and mortality in CF, and our team members have over decades developed incredible expertise in their studies of CF that now can be used to develop important, mechanistic insights into NCFBE. We are proud of our submitted proposal, and hope the NIH likes it, too! Will keep you posted.

We are very excited to welcome the entire CF community to Atlanta next week for the North American CF Conference to be held downtown, Oct 7-9. It's an excellent conference, covering research as well as clinical care. Non-professionals are welcome to join; you can see the program here: [North American Cystic Fibrosis Conference](#) | [North American Cystic Fibrosis Conference](#). The CF@LANTA/CF-AIR team will be very well represented in this conference, leading sessions and presenting their science and clinical insights in both oral and poster form. Please see the long list of our team's engagement on our website here: [News and Events](#).

In addition, we are taking this opportunity to hold the inaugural CF Data Science Workshop on Oct 6, all day, and also have planned a special CF@LANTA event in the evening of Oct 6. Registration for the Workshop is found at the same link above - registration will close on Oct 2, so please take a look quickly if you can.

We look forward to seeing many of you in Atlanta next week!

All the best,
Nael

In This Issue

2 CF-AIR & CF@LANTA at NACFC

3 Research Highlights & Kudos

4 Spotlight: PCD Program

6-8 Publications

9 Science Huddle Schedule

10 Connect with Us

CF-AIR & CF@LANTA at NACFC

North American Cystic Fibrosis Conference (NACFC) October 6-10, 2026 in Atlanta, Georgia

We are excited to welcome the cystic fibrosis research and care community to Atlanta for NACFC. In addition to the conference, we are hosting two special events on **Tuesday, October 6th**.

CF Data Science Workshop

Time: 8:00 AM – 5:00 PM

Location: National Center for Civil and Human Rights

This free, one-day workshop will explore how data science can advance cystic fibrosis research and care.

The program will highlight the Georgia CF Data Exchange & Warehouse (GACFDEW), a cloud-based platform that integrates longitudinal clinical, research, and biorepository data from people with CF across Georgia.

Sessions will cover:

- Data science needs and opportunities in CF
- Existing data resources and infrastructure
- Data integration, standardization, and ethics
- Real-world applications of data science

The workshop will conclude with a hands-on mini-hackathon using de-identified datasets.

Register [here](#)!

CF@LANTA Welcome Reception

Honoring Mr. Andy Lipman

Time: 6:00 PM – 8:30 PM (Complimentary Access to NCCHR Exhibits for attendees 4:00-6:00 PM)

Location: National Center for Civil and Human Rights

We will be welcoming our team to NACFC and national leaders to Atlanta, as well as connecting with colleagues across the CF community.

The reception will include:

- Opening remarks from CF@LANTA leadership
- A celebration of key milestones across our research, adult clinical, and pediatric clinical programs
- Networking with researchers, clinicians, trainees, and community partners
- Launch of the Andy Lipman Program in Wellness in CF



Research Highlights and Kudos

Featured Investigators at NACFC

We are looking forward to this year's **North American Cystic Fibrosis Conference (NACFC) in Atlanta**. Emory University, Children's Healthcare of Atlanta, and affiliate faculty, trainees, staff, and students will be taking part as speakers, chairs, poster presenters, and panelists throughout the meeting.

Please find the detailed schedule linked [here](#), highlighting our participation at NACFC.

Kudos to Our Investigators



- CF-AIR members **Jocelyn Grunwell, MD, PhD, Jacob Kohlmeier, PhD, Claudia Morris, MD, FAAP, Lawrence Phillips, MD, and Samantha Yeligar, PhD** for their recognition on [Emory School of Medicine 2026 Researcher Appreciation Day](#).
- **Ajay Kasi, MD**, co-author on "[Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years \(TIMBERLINE Trial VX21-121-105\): a phase 3, open-label study,](#)" published in *The Lancet Respiratory Medicine*. Dr. Kasi served as lead national PI for this study.
- **Anne Fitzpatrick, PhD, RN, APRN**, co-author on "[Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial,](#)" published in the *The Lancet*.
- **Kat Brave, PhD**, for the Young Investigator Award at the [Society for Redox Biology and Medicine 2026 North American Redox Symposium](#), highlighting the symposium's role in fostering next generation redox scientists and celebrating innovative research contributions.
- **Ashlyn Winters**, chosen to give a talk at the [Translational Control meeting at the Cold Spring Harbor Laboratory \(CSHL\)](#) on "Distinct mechanisms of nonsense suppression revealed by targeting ribosomal proteins on opposing sides of the peptidyltransferase center."

Research Spotlight

Primary Ciliary Dyskinesia (PCD) Program

Started in 2021, the Children's Healthcare of Atlanta **Primary Ciliary Dyskinesia (PCD) program** is the only accredited pediatric Clinical and Research Center Network (CRCN) Primary Ciliary Dyskinesia (PCD) program in the state of Georgia. In 2025, the Adult PCD clinic at Emory University also received its accreditation by the PCD Foundation, making Emory one of the few centers in the country that have both pediatric and adult PCD programs. We are currently one of the largest programs in the country in terms of confirmed PCD diagnoses. Our PCD team is comprised of 6 PCD pulmonologists (4 pediatric and 2 adult), 1 research coordinator, 1 Respiratory Therapist, and 1.5 Nurse FTE.

The pediatric program is co-directed by Drs. Lokesh Guglani and Jonathan Popler. The adult PCD program is co-directed by Drs. Colin Swenson and William R. Hunt. Dr. Guglani also serves on the Data Oversight Committee and the Genomics Committee of the PCD Foundation Patient Registry.

The PCD program at Emory and Children's Healthcare of Atlanta presented four research posters and an oral presentation at the Global PCD Conference 2026 in Montreal, Canada from August 19-22, 2026.

Posters:

- Guglani L, Ozel E, Silva GL, Dias A, Vala S, Popler J, Hastings ML, Takayama S, Oliver KE. Diving deeper into the genome: Evidence for expanded contributions of intronic variants to PCD cases.
- Fain ME, Silva GL, Chandler J, Kopp B, Guglani L. Non-invasive assessment of upper and lower airway inflammatory markers in pediatric patients with Primary Ciliary Dyskinesia.
- Giraldo DM, Li Z, Padmanabhan S, Silva GL, Anwar A, Driggers C, Browne E, Chandler JD, Stecenko A, Swenson C, Tirouvanziam R, Guglani L. Phenotyping of Primary Ciliary Dyskinesia Sputum Immune Cells and Mediators Reveal a Characteristic "GRIM" Neutrophil Signature.
- Browne E, Padmanabhan S, Giraldo DM, Silva GL, Anwar A, Driggers C, Chandler JD, Swenson C, Stecenko A, Guglani L, Tirouvanziam R. Transmigration of human blood neutrophils into Primary Ciliary Dyskinesia sputum drives inflammatory pathology.

Oral Presentation:

- Fain ME, Rajwal S, Diaz-Asper K, Silva GL, Sarker A, Guglani L. Assessing the performance of large language models on diagnostic reasoning for Primary Ciliary Dyskinesia in pediatric patients.

In addition, the PCD team has also been deeply engaged with the use of Artificial Intelligence (AI) in relation to diagnostic evaluation and work up of PCD. Here are the AI related presentations at recent conferences:

- Rajwal S, Fain ME, Guglani L, Sarker A. Confident but Mis-Aligned: Note-Anchoring and Opacity of Uncertainty as Grand Challenges for Clinical LLM Deployment. Abstract paper submitted for ACM AI Leadership Summit, Aug 30-Sep-2, 2026, Atlanta GA.
- Rajwal S, Fain ME, Diaz-Asper K, Silva GL, Sarker A, Guglani L. Assessing the Performance of Large Language Models for Diagnostic Reasoning for Primary Ciliary Dyskinesia in Pediatric Patients. Poster presentation at American Thoracic Society Conference 2026 (May 15-20, 2026) at Orlando FL.

Genetic testing remains one of the key tests for establishing the diagnosis of PCD, and our PCD team has been at the forefront of recognizing several rare intronic variants related to PCD and other genetic causes of non-CF bronchiectasis. Work has been presented at several conferences and is being submitted for a few publications.

- Ozel E, Silva GL, Popler J, Dias A, Guglani L, Mori M. Brushing up on Primary Ciliary Dyskinesia: A Pediatric Case Series with a Shared CCDC39 c.1167+1261A>G Variant and African Ancestry. Poster presentation at American College of Medical Genetics Conference at Baltimore, MD. March 10-14, 2026.
- Popler J, Dias A, Kelly K, Page S, Starks M, Silva GL, Vala S, Guglani L. WFDC2-Related Bronchiectasis and Nasal Polyposis Masquerading as Primary Ciliary Dyskinesia in an Adolescent. Manuscript under review at Pediatric Pulmonology Journal.
- Guglani L, Ing A, Ozel E, Al-Jaberi R, Silva GL, Dias A, Vala S, Popler J, Oliver KE. Noncoding Variants in Primary Ciliary Dyskinesia: A Single-Center Case Series. Submitted for publication – American Journal of Medical Genetics.

Publications Since Our Last Newsletter



Kudos to our CF-AIR/CF@LANTA investigators

A novel drug series optimized to address cystic fibrosis and other CFTR deficiency diseases of human airways, *NPJ Drug Discov.*, 2025 Nov 3.

Vanadyl sulfate supplementation alters the intestinal microbiome and bile acid metabolism, *Toxicol Appl Pharmacol.*, 2025 Dec.

Single-cell multiomic analysis of mesenchymal cells reveals molecular signatures and regulators of lung allograft fibrosis, *JCI Insight*, 2026 Apr 23.

Active Chlorine Antiseptics in Wound Care: Recent Advances and Perspectives for Military Medicine, *APMIS*, 2026 Jun.

Beyond The Nucleus: Translating Engineered Protein Localization To Chromatin Modifying Enzymes, *Curr Opin Biomed Eng*, 2026 Jun.

Clinical outcomes in food allergy: Implications for patients, clinicians, and health systems, *Ann Allergy Asthma Immunol.*, 2026 Jun.

The Science and Art of Neonatal Respiratory Care, *Clin Perinatol.*, 2026 Jun.

Evaluating the effects of CD8/CD4 on T cell function in terms of TCR-pMHC-coreceptor catch and slip bonds, *Front Immunol.*, 2026 Jun 5.

Structural Diversity and Analytical Characterization of Acylhomocarnitines, *J Proteome Res.*, 2026 Jun 5.

Myeloid-avid mammalian target of rapamycin-inhibiting nanobiologic attenuates allograft fibrosis after lung transplantation, *Am J Transplant.*, 2026 Jun 6.

Prediction of Mesenchymal Stromal Cell Immune Suppression Using Live Imaging in a Three-Dimensional Microfluidic Device, *ACS Biomater Sci Eng.*, 2026 Jun 8.

Profiling the CFTR Variant Selectivity and Off-Target Interactions of VX-121, *bioRxiv [Preprint]*, 2026 Jun 8.

The Wheezing, Asthma and Viral effects on the Epithelial Structure and function (WAVES) birth cohort study: rationale, design and methods to understand airway development and the role of early-life respiratory viral infections on childhood asthma inception, *BMJ Open Respir Res.*, 2026 Jun 9.

Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical Trial, *Ann Am Thorac Soc.*, 2026 Jun 10.

The Guild Model of CF Airway Microbial Ecology, *mBio.*, 2026 Jun 10.

Host and antibiotic jointly select for greater virulence in *Staphylococcus aureus*, *Elife*, 2026 Jun 16.

Concise synthesis of simplified aogacillin analogs reveals innate reactivity and synergy with aminoglycosides, *Chem Sci.*, 2026 Jun 19.

A polyvalent phage shapes bacterial dynamics, *J Virol.*, 2026 Jun 23.

Mass spectrometry as the unifying force in natural product sciences, *Nat Prod Rep.*, 2026 Jun 26.

Mass spectrometry-based metabolomics approaches to interrogate host-microbiome interactions in mammalian systems, *Nat Prod Rep.*, 2026 Jun 26.

Click to link to the publication. Full citations available at <https://cfatl.org/recent-publications>.

Publications Since Our Last Newsletter



Kudos to our CF-AIR/CF@LANTA investigators

Healthcare priorities and needs for LGBTQIA+ people with cystic fibrosis: A concept mapping study, *J Cyst Fibros.*, 2026 Jun 29.

Development of a microneedle patch for delivery of mRNA-lipid nanoparticles, *Drug Deliv Transl Res.*, 2026 Jul.

Distinct signaling mechanisms and proteome phenotypes are elicited by compartment-specific genetic defects of copper homeostasis, *Mol Biol Cell.*, 2026 Jul.

From the pages of AllergyWatch, *Ann Allergy Asthma Immunol.*, 2026 Jul.

Global Group Testing and Screening With Dynamic Effects, *Stat Sin.*, 2026 Jul.

"It Felt Like Throwing in the Towel": Family Caregiver Perspectives on End-of-Life Decision Making in Chronic Obstructive Pulmonary Disease, *J Palliat Med.*, 2026 Jul.

A microgel bone marrow model of mesenchymal stromal cell paracrine signaling supporting hematopoietic stem cell retention, *Acta Biomater.*, 2026 Jul.

Updates in Cystic Fibrosis Bone Disease in Adults, *Endocr Pract.*, 2026 Jul.

A prospective study of high-impact chronic pain in sickle cell disease: the Sickle Pain-Related Impact (SPiRIIt) study, *Pain.*, 2026 Jul 1.

Untargeted serum metabolomics and air pollution in Parkinson's disease, *NPJ Parkinsons Dis.*, 2026 Jul 1.

Mucin-induced metabolic reprogramming in *Pseudomonas aeruginosa* clinical isolates, *mSystems*, 2026 Jul 2.

Sparse CCA-based mediation analysis with high-dimensional exposures and mediators, *Bioinformatics*, 2026 Jul 2.

Intraspecific diversity of *Staphylococcus aureus* populations isolated from cystic fibrosis respiratory infections, *Microbiol Spectr.*, 2026 Jul 6.

Scholarly Skills Series: How to Succeed in Writing Case Reports, *J Palliat Med.*, 2026 Jul 7.

Effects of a low-glycaemic, moderately carbohydrate-restricted diet on hepatic lipid content and insulin sensitivity in adolescents with metabolic dysfunction-associated steatotic liver disease: protocol of a 6-month family-based, randomised controlled trial, *Br J Nutr.*, 2026 Jul 13.

Pervasive interactions between exposures and polygenic risk can inform more effective clinical and behavioral interventions, *Nat Genet.*, 2026 Jul 13.

Biosocial influences of gender identity and geography on mucosal microbial phenotypes, *Commun Med (Lond)*, 2026 Jul 14.

I-STRONG: an integrative, multicomponent treatment approach for chronic pain in pediatric sickle cell disease, *Blood Adv.*, 2026 Jul 14.

Non-uniform susceptibility profiles observed in *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* toward both front-line and novel cationic biocides with diverse structural compositions, *Microbiol Spectr.*, 2026 Jul 16.

Factors governing the response of *Pseudomonas aeruginosa* to hypothiocyanous acid, *Front Cell Infect Microbiol.*, 2026 Jul 17

Click to link to the publication. Full citations available at <https://cfatl.org/recent-publications>.

Publications Since Our Last Newsletter



Kudos to our CF-AIR/CF@LANTA investigators

Radiomics of the Airway (RadAr): Multi-Scale Airway Phenotyping for Disease Characterization on Routine CT Imaging, *medRxiv [Preprint]*, 2026 Jul 21.

Mechanistic Insights into Redox-Dependent Macropinocytosis in Primary Human Neutrophils, *Antioxidants (Basel)*, 2026 Jul 21.

Mucin-induced metabolic reprogramming in *Pseudomonas aeruginosa* clinical isolates, *mSystems*, 2026 Jul 21.

Correcting serum phosphate homeostasis does not alleviate the health dangers of high phosphate consumption, *J Transl Med.*, 2026 Jul 22.

A Novel Tool for Assessing the Content and Quality of Goals of Care Documentation, *J Palliat Med.*, 2026 Jul 24.

SynNotch receptors for visualizing immunoreceptor force transmission and downstream signaling in vivo, *bioRxiv [Preprint]*, 2026 Jul 25.

Treatment of Multifood Allergy With Omalizumab or Multiallergen Oral Immunotherapy: A Randomized Clinical Trial, *JAMA Pediatr.*, 2026 Jul 27.

Immune cells harbor their own microbiome-derived metabolome: a new layer of immunometabolic regulation, *Front Immunol.*, 2026 Jul 28.

LRRK2 G2019S reprograms innate and adaptive immunity to drive context-dependent host defense outcomes, *Front Cell Neurosci.*, 2026 Jul 29.

The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis, *Lancet Respir Med.*, 2026 Aug.

Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia (SILDI-SAFE): A Randomized Controlled Trial, *J Pediatr.*, 2026 Aug.

Subtypes of Type 2 Diabetes and Prediabetes: Mortality and Excess Life Lost in South Asians, *Diabetes Care.*, 2026 Aug 1.

Infant Infection With Respiratory Syncytial Virus Genotypes and Subsequent Childhood Asthma Risk, *J Infect Dis.*, 2026 Aug 3.

Intraspecific diversity of *Staphylococcus aureus* populations isolated from cystic fibrosis respiratory infections, *Microbiol Spectr.*, 2026 Aug 4.

Growing *Staphylococcus aureus* in synthetic cystic fibrosis medium promotes colonization in a murine pneumonia model, *Infect Immun.*, 2026 Aug 6.

Single-cell RNA sequencing reveals dysregulation of innate immune signaling in early-life respiratory syncytial virus infection with subsequent low-level cadmium exposure, *Toxicol Rep.*, 2026 Aug 6.

Suppressive genetic interactions between haploinsufficient mitochondrial genes encoded in the 22q11.2 microdeletion locus define brain and cardiac phenotypes, *Hum Mol Genet.*, 2026 Aug 10.

Non-invasive nanoparticle barcoding in nonhuman primates, *Nat Biotechnol.*, 2026 Aug 11.

Click to link to the publication. Full citations available at <https://cfatl.org/recent-publications>.

Publications Since Our Last Newsletter



Kudos to our CF-AIR/CF@LANTA investigators

Reply: Statistical Fragility and Methodological Constraints in Metabolomic Mediation of Air Pollution and Cardiovascular Risk, *JACC Adv.*, 2026 Aug 12.

Low Cord Blood Titers Are Associated with Prolonged Maternal RSV Antibody Half-Lives in Preterm Infants, *J Infect Dis.*, 2026 Aug 13.

Pharmacoexposomics: The Environmental Complement to Pharmacogenomics to Advance Precision Medicine, *Annu Rev Pharmacol Toxicol.*, 2026 Aug 13.

Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome, *Sci Adv.*, 2026 Aug 14.

Inhaled dry powders of mRNA polyplexes prepared by thin-film freeze-drying, *Int J Pharm.*, 2026 Aug 17.

Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STaRT Randomized Clinical Trial, *JAMA*, 2026 Aug 19.

Azithromycin for Preschoolers with Wheezing in the Emergency Department, *N Engl J Med.*, 2026 Aug 20.

Placental Histopathology and Transplacental Transfer of RSV-specific Neutralizing Antibodies The Silver Study, *Pediatr Infect Dis J.*, 2026 Aug 20.

Navigating physician-scientist careers: insights from American Board of Internal Medicine Research Pathway graduates, *JCI Insight*, 2026 Aug 24.

Scholarly Skills Series: How to Succeed in Writing Case Reports, *J Palliat Med.*, 2026 Sep.

The Orphaned Science of Perinatal Pharmacology, *Clin Perinatol.*, 2026 Sep.

From the pages of AllergyWatch, *Ann Allergy Asthma Immunol.*, 2026 Sep 1.

"I feel like you should buy an umbrella before it starts raining": caregiver perspectives on illness inflection points in chronic obstructive pulmonary disease, *Ann Am Thorac Soc.*, 2026 Sep 1.

Respiratory Syncytial Virus Hospitalizations in Adults ≥ 50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020, *Clin Infect Dis.*, 2026 Sep 2.

Balanced Fluid or 0.9% Saline in Children Treated for Septic Shock, *N Engl J Med.*, 2026 Sep 3.

Uncovering the mechanism of action of a historical antimicrobial against *S. aureus* and *A. baumannii*, *mSphere*, 2026 Sep 3.

Local delivery of rhBMP-2 affects systemic metabolic response during healing of critically-sized segmental defects in a rat model, *Bone.*, 2026 Oct.

Paediatric Drug Optimization for Sickle Cell Disease: priorities for research and development in children, *Lancet Child Adolesc Health*, 2026 Oct.

Project Sickle Cure: A Prospective, International Observational Study of Hematopoietic Cell Transplantation for Sickle Cell Disease, *Eur J Haematol.*, 2026 Oct.

Secretory Phospholipase A₂ in Patients With Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain Episodes, *Pediatr Blood Cancer*, 2026 Oct.

Click to link to the publication. Full citations available at <https://cfatl.org/recent-publications>.

CF-AIR Science Huddle Schedule

FALL 2026 SCHEDULE

Date	Time	Type	Presenter
1-Oct	12-2 PM	Journal Club	NACFC Practice Talk Session
6-Oct	8 AM-5 PM	Special Event	CF Data Science Workshop
15-Oct	12-2 PM	Journal Club	What We Learned at NACFC
22-Oct	1-2 PM	Research Highlight	Sohail Khoshnevis, PhD
29-Oct	1-2 PM	Social	Halloween Social
5-Nov	1-2 PM	Guest Lecturer	Patrick Harrison, PhD (Cincinnati)
12-Nov	1-2 PM	Journal Club	Erica Browne
19-Nov	1-2 PM	Trainee Focused	Malinda Wu, MD, MSCR (Johns Hopkins)
3-Dec	1-2 PM	Guest Lecturer	Finn Hawkins, M.B., B.Ch. (Boston University)
10-Dec	1-2 PM	Social	Holiday Social/White Elephant Gift Exchange

SPRING 2027 SCHEDULE


Date	Time	Type	Presenter
7-Jan	1-2 PM	Journal Club	Jon Dudkin
14-Jan	1-2 PM	Guest Lecturer	Lisa T. Jansen, Ph.D. (University of Arkansas)
21-Jan	1-2 PM	Trainee Focused	Jonica Brown/Su Yeon Oh
28-Jan	2-3 PM	Research Highlight	Mike Koval, PhD
4-Feb	1-2 PM	Guest Lecturer	CF Family Ed Day Speaker
11-Feb	1-2 PM	Trainee Focused	Eduardo Martinez Marin
18-Feb	1-2 PM	Trainee Focused	Canan Karakoc, PhD/JaNise Jackson, PhD
25-Feb	1-2 PM	Research Highlight	Paul A. Dawson, PhD, FAASLD
4-Mar	1-2 PM	Guest Lecturer	Judy Voynow, MD (Children's Hospital of Richmond at VCU)
11-Mar	1-2 PM	Journal Club	Laura Rotolo, PhD
18-Mar	1-2 PM	Trainee Focused	Abby Wilson/Elijah Mehlferber, PhD
25-Mar	1-2 PM	Research Highlight	Thomas R. Ziegler, MD, MS
1-Apr	1-2 PM	Guest Lecturer	TBD
8-Apr	1-2 PM	Research Highlight	Stephanie Eick, PhD
15-Apr	1-2 PM	Trainee Focused	Joe Shapiro/Erica Browne
22-Apr	1-2 PM	Research Highlight	Leslie Chan, PhD
29-Apr	1-2 PM	Social	Birthdays/Spring Social
6-May	1-2 PM	Guest Lecturer	Jason Debley, MD, MPH (Seattle Children's)
13-May	1-2 PM	Journal Club	Janiyah White
20-May	1-2 PM	Trainee Focused	Laura Rotolo, PhD/Sujay Greenlund
27-May	1-2 PM	Research Highlight	James Gurney, PhD (Georgia State)

Around the Research Organization

Pediatric Core Services

Offer the equipment, tools, and skilled professionals to make research faster and more impactful. From imaging and data analysis to clinical trial support, our pediatric cores provide key resources and expert support to help researchers at every step. Researchers, check out details about our pediatric research core services [here](#) or via the QR code.

For questions or details, please reach out to Cores Administrator, [Kevin Loop-Tapp](#).



Connect with CF-AIR & CF@LANTA

Visit Our Websites

[CF@LANTA](#)



[CF-AIR](#)

Join Our Listserv

Would you like to receive information and calendar invites about CF-AIR & CF@LANTA Seminars and other news? Email megan.stewart@emory.edu and request to be added to our listserv!



CF-AIR is now on BlueSky! Follow us and tag us [@emory-choa-cfair.bsky.social](#)

Follow and tag us on X [@EmoryCHOA_CFAIR](#) and [@CFAtlanta](#)

